Advanced search
Publication Cover
Immunotherapy Volume 2, 2010 - Issue 1
Submit an article Journal homepage
168
Views
0
CrossRef citations to date
0
Altmetric
Review

T-Cell Based Immunotherapy in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis

Kate O‘Brien1 Division of Clinical Neurology, University of Nottingham, UK
,
Bruno Gran1 Division of Clinical Neurology, University of Nottingham, UK;2 Department of Neurology, Thomas Jefferson University, Philadelphia, PA19107, US. Tel.: +1 215 955 8100 Fax: +1 215 955 [email protected]
&
Abdolmohamad Rostami2 Department of Neurology, Thomas Jefferson University, Philadelphia, PA19107, US. Tel.: +1 215 955 8100 Fax: +1 215 955 [email protected]
Pages 99-115 | Published online: 17 Dec 2009

Bibliography

  • Noseworthy JH , LucchinettiC, RodriguezM, WeinshenkerBG: Multiple sclerosis.N. Engl. J. Med.343(13) , 938–952 (2000).
  • Sospedra M , MartinR: Immunology of multiple sclerosis.Annu. Rev. Immunol.23 , 683–747 (2005).
  • Grigoriadis N , HadjigeorgiouGM: Virus-mediated autoimmunity in multiple Sclerosis.J. Autoimmune Dis.3 , 1 (2006).
  • Trapp BD , PetersonJ, RansohoffRM et al.: Axonal transection in the lesions of multiple sclerosis.N. Engl. J. Med.338(5) , 278–285 (1998).
  • Peterson JW , BoL, MorkS, ChangA, TrappBD: Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions.Ann. Neurol.50(3) , 389–400 (2001).
  • Becher B , DurellBG, NoelleRJ: Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12.J. Clin. Invest.110(4) , 493–497 (2002).
  • Chen Y , LangrishCL, McKenzieB et al.: Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis.J. Clin. Invest.116(5) , 1317–1326 (2006).
  • Gran B , Zhang G-X, Yu S et al.: IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination. J. Immunol.169(12) , 7104–7110 (2002).
  • Komiyama Y , NakaeS, MatsukiT et al.: IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis.J. Immunol.177(1) , 566–573 (2006).
  • Langrish CL , ChenY, BlumenscheinWM et al.: IL-23 drives a pathogenic T cell population that induces autoimmune inflammation.J. Exp. Med.201(2) , 233–240 (2005).
  • Mosmann TR , CoffmanRL: Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties.Annu. Rev. Immunol.7 , 145–173 (1989).
  • Romagnani S , ParronchiP, D‘EliosMM et al.: An update on human Th1 and Th2 cells.Int. Arch. Allergy Immunol.113(1–3) , 153–156 (1997).
  • Oppmann B , LesleyR, BlomB et al.: Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12.Immunity13(5) , 715–725 (2000).
  • Segal BM , ShevachEM: IL-12 unmasks latent autoimmune disease in resistant mice.J. Exp. Med.184(2) , 771–775 (1996).
  • Segal BM , DwyerBK, ShevachEM: An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease.J. Exp. Med.187(4) , 537–546 (1998).
  • Cua DJ , SherlockJ, ChenY et al.: Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain.Nature421(6924) , 744–748 (2003).
  • Gran B , ChuN, ZhangGX et al.: Early administration of IL-12 suppresses EAE through induction of interferon-γ.J. Neuroimmunol.156(1–2) , 123–131 (2004).
  • Aggarwal S , GhilardiN, Xie M-H, de Sauvage FJ, Gurney AL: Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem.278(3) , 1910–1914 (2003).
  • Bettelli E , CarrierY, GaoW et al.: Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells.Nature (2006).
  • Gutcher I , UrichE, WolterK, PrinzM, BecherB: Interleukin 18-independent engagement of interleukin 18 receptor-a is required for autoimmune inflammation.Nat. Immunol.7(9) , 946–953 (2006).
  • Liang SC , TanXY, LuxenbergDP et al.: Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides.J. Exp. Med.203(10) , 2271–2279 (2006).
  • Veldhoen M , HockingRJ, AtkinsCJ, LocksleyRM, StockingerB: TGF-β in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells.Immunity24(2) , 179–189 (2006).
  • Korn T , BettelliE, GaoW et al.: IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells.Nature448(7152) , 484–487 (2007).
  • Nurieva R , YangXO, MartinezG et al.: Essential autocrine regulation by IL-21 in the generation of inflammatory T cells.Nature448(7152) , 480–483 (2007).
  • Batten M , LiJ, YiS et al.: Interleukin-27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells.Nat. Immunol.7(9) , 929–936 (2006).
  • Stumhofer JS , LaurenceA, WilsonEH et al.: Interleukin-27 negatively regulates the development of interleukin 17- producing T helper cells during chronic inflammation of the central nervous system.Nat. Immunol.7(9) , 937–945 (2006).
  • Laurence A , TatoCM, DavidsonTS et al.: Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation.Immunity26(3) , 371–381 (2007).
  • Sakaguchi S : Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses.Ann. Rev. Immunol.22(1) , 531–562 (2004).
  • Traugott U , ReinherzEL, RaineCS: Multiple sclerosis. Distribution of T cells, T-cell subsets and Ia-positive macrophages in lesions of different ages.J. Neuroimmunol.4(3) , 201–221 (1983).
  • Brostoff SW , MasonDW: Experimental allergic encephalomyelitis: successful treatment in vivo with a monoclonal antibody that recognizes T helper cells.J. Immunol.133(4) , 1938–1942 (1984).
  • Pettinelli CB , McFarlinDE: Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for Lyt 1+ 2-T lymphocytes.J. Immunol.127(4) , 1420–1423 (1981).
  • Waldor MK , SriramS, HardyR et al.: Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T-cell subset marker.Science227(4685) , 415–417 (1985).
  • Hemmer B , HartungHP: Toward the development of rational therapies in multiple sclerosis: what is on the horizon?Ann. Neurol.62(4) , 314–326 (2007).
  • Compston A : The genetics of multiple sclerosis.J. Neurovirol.6(Suppl. 2) , S5–S9 (2000).
  • Hafler DA , CompstonA, SawcerS et al.: Risk alleles for multiple sclerosis identified by a genomewide study.N. Engl. J. Med.357(9) , 851–862 (2007).
  • Haines JL , Ter-MinassianM, BazykA et al.: A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group.Nat. Genet.13(4) , 469–471 (1996).
  • Babbe H , RoersA, WaismanA et al.: Clonal expansions of CD8+ T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction.J. Exp. Med.192(3) , 393–404 (2000).
  • Jacobsen M , CepokS, QuakE et al.: Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients.Brain125(3) , 538–550 (2002).
  • Miller A , HaflerDA, WeinerHL: Tolerance and suppressor mechanisms in experimental autoimmune encephalomyelitis: implications for immunotherapy of human autoimmune diseases.FASEB J.5(11) , 2560–2566 (1991).
  • Racke MK , BonomoA, ScottDE et al.: Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease.J. Exp. Med.180(5) , 1961–1966 (1994).
  • Liblau RS , TischR, ShokatK et al.: Intravenous injection of soluble antigen induces thymic and peripheral T-cells apoptosis.Proc. Natl Acad. Sci. USA93(7) , 3031–3036 (1996).
  • Kearney ER , PapeKA, LohDY, JenkinsMK: Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo.Immunity1(4) , 327–339 (1994).
  • Miller A , ZhangZJ, SobelRA, al-SabbaghA, WeinerHL: Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. VI. Suppression of adoptively transferred disease and differential effects of oral vs. intravenous tolerization.J. Neuroimmunol.46(1–2) , 73–82 (1993).
  • Miller SD , McRaeBL, VanderlugtCL et al.: Evolution of the T-cell repertoire during the course of experimental immune-mediated demyelinating diseases.Immunol. Rev.144 , 225–244 (1995).
  • Tan JK , O‘NeillHC: Maturation requirements for dendritic cells in T-cell stimulation leading to tolerance versus immunity.J. Leukoc. Biol.78(2) , 319–324 (2005).
  • Baker D , O‘NeillJK, GschmeissnerSE et al.: Induction of chronic relapsing experimental allergic encephalomyelitis in Biozzi mice.J. Neuroimmunol.28(3) , 261–270 (1990).
  • Pryce G , O‘NeillJK, CroxfordJL et al.: Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis.J. Neuroimmunol.165(1–2) , 41–52 (2005).
  • Hilliard B , VenturaES, RostamiA: Effect of timing of intravenous administration of myelin basic protein on the induction of tolerance in experimental allergic encephalomyelitis.Mult. Scler.5(1) , 2–9 (1999).
  • Hilliard BA , KamounM, VenturaE, RostamiA: Mechanisms of suppression of experimental autoimmune encephalomyelitis by intravenous administration of myelin basic protein: role of regulatory spleen cells.Exp. Mol. Pathol.68(1) , 29–37 (2000).
  • Zhang GX , YuS, LiY et al.: A paradoxical role of APCs in the induction of intravenous tolerance in experimental autoimmune encephalomyelitis.J. Neuroimmunol.161(1–2) , 101–112 (2005).
  • Li H , ZhangGX, ChenY et al.: CD11c+CD11b+ dendritic cells play an important role in intravenous tolerance and the suppression of experimental autoimmune encephalomyelitis.J. Immunol.181(4) , 2483–2493 (2008).
  • Jiang Z , LiH, FitzgeraldDC, ZhangGX, RostamiA: MOG (35–55) i.v suppresses experimental autoimmune encephalomyelitis partially through modulation of Th17 and JAK/STAT pathways.Eur. J. Immunol.39(3) , 789–799 (2009).
  • London CA , LodgeMP, AbbasAK: Functional responses and costimulator dependence of memory CD4+ T cells.J. Immunol.164(1) , 265–272 (2000).
  • Verbeek R , van der Mark K, Wawrousek EF, Plomp AC, van Noort JM: Tolerization of an established αβ-crystallin-reactive T-cell response by intravenous antigen. Immunology121(3) , 416–426 (2007).
  • Bai XF , ShiFD, XiaoBG et al.: Nasal administration of myelin basic protein prevents relapsing experimental autoimmune encephalomyelitis in DA rats by activating regulatory cells expressing IL-4 and TGF-β mRNA.J. Neuroimmunol.80(1–2) , 65–75 (1997).
  • Burkhart C , LiuGY, AndertonSM, MetzlerB, WraithDC: Peptide-induced T cell regulation of experimental autoimmune encephalomyelitis: a role for IL-10.Int. Immunol.11(10) , 1625–1634 (1999)
  • Bitar DM , WhitacreCC: Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein.Cell Immunol.112(2) , 364–370 (1988).
  • Higgins PJ , WeinerHL: Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments.J. Immunol.140(2) , 440–445 (1988).
  • Weiner HL , MackinGA, MatsuiM et al.: Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis.Science259(5099) , 1321–1324 (1993).
  • Faria AM , WeinerHL: Oral tolerance.Immunol. Rev.206 , 232–259 (2005).
  • Ochi H , AbrahamM, IshikawaH et al.: Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+CD25-LAP+ T cells.Nat. Med.12(6) , 627–635 (2006).
  • Evavold BD , AllenPM: Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand.Science252(5010) , 1308–1310 (1991).
  • Racioppi L , RoncheseF, MatisLA, GermainRN: Peptide-major histocompatibility complex class II complexes with mixed agonist/antagonist properties provide evidence for ligand-related differences in T cell receptor-dependent intracellular signaling.J. Exp. Med.177(4) , 1047–1060 (1993).
  • De Magistris MT , AlexanderJ, CoggeshallM et al.: Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor.Cell68(4) , 625–634 (1992).
  • Brocke S , GijbelsK, AllegrettaM et al.: Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein.Nature379(6563) , 343–346 (1996).
  • Goverman J , WoodsA, LarsonL et al.: Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity.Cell72(4) , 551–560 (1993).
  • Brabb T , GoldrathAW, von Dassow P et al.: Triggers of autoimmune disease in a murine TCR-transgenic model for multiple sclerosis. J. Immunol.159(1) , 497–507 (1997).
  • Lafaille JJ , NagashimaK, KatsukiM, TonegawaS: High incidence of spontaneous autoimmune encephalomyelitis in immunodeficient anti-myelin basic protein T cell receptor transgenic mice.Cell.78(3) , 399–408 (1994).
  • Offner H , AdlardK, BeboBF Jr et al.: Vaccination with BV8S2 protein amplifies TCR-specific regulation and protection against experimental autoimmune encephalomyelitis in TCR BV8S2 transgenic mice. J. Immunol.161(5) , 2178–2186 (1998).
  • Vandenbark AA , RichC, MooneyJ et al.: Recombinant TCR ligand induces tolerance to myelin oligodendrocyte glycoprotein 35–55 peptide and reverses clinical and histological signs of chronic experimental autoimmune encephalomyelitis in HLA-DR2 transgenic mice.J. Immunol.171(1) , 127–133 (2003).
  • Moisini I , NguyenP, FuggerL, GeigerTL: Redirecting therapeutic T cells against myelin-specific T lymphocytes using a humanized myelin basic protein-HLA-DR2-ζ chimeric receptor.J. Immunol.180(5) , 3601–3611 (2008).
  • Ito K , BianHJ, MolinaM et al.: HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis.J. Exp. Med.183(6) , 2635–2644 (1996).
  • Muraro PA , VergelliM, KalbusM et al.: Immunodominance of a low-affinity major histocompatibility complex-binding myelin basic protein epitope (residues 111–129) in HLA-DR4 (B1*0401) subjects is associated with a restricted T cell receptor repertoire.J. Clin. Invest.100(2) , 339–349 (1997).
  • Huh J , YaoK, QuigleyL et al.: Limited repertoire of HLA-DRB1*0401-restricted MBP111–129-specific T cells in HLA-DRB1*0401 Tg mice and their pathogenic potential.J. Neuroimmunol.151(1–2) , 94–102 (2004).
  • Fridkis-Hareli M , TeitelbaumD, GurevichE et al.: Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells – specificity and promiscuity.Proc. Natl Acad. Sci. USA91(11) , 4872–4876 (1994).
  • Vandenbark AA , ChouYK, WhithamR et al.: Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial.Nat. Med.2(10) , 1109–1115 (1996).
  • Vandenbark AA , MorganE, BartholomewR et al.: TCR peptide therapy in human autoimmune diseases.Neurochem. Res.26(6) , 713–730 (2001).
  • Bielekova B , GoodwinB, RichertN et al.: Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: results of a Phase II clinical trial with an altered peptide ligand.Nat. Med.6(10) , 1167–1175 (2000).
  • Leonard JP , WaldburgerKE, GoldmanSJ: Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin-12.J. Exp. Med.181(1) , 381–386 (1995).
  • Constantinescu CS , WysockaM, HilliardB et al.: Antibodies against IL-12 prevent superantigen-induced andspontaneous relapses of experimental autoimmune encephalomyelitis.J. Immunol.161(9) , 5097–5104 (1998).
  • Ichikawa M , KohCS, InoueA et al.: Anti-IL-12 antibody prevents the development and progression of multiple sclerosis-like relapsing–remitting demyelinating disease in NOD mice induced with myelin oligodendrocyte glycoprotein peptide.J. Neuroimmunol.102(1) , 56–66 (2000).
  • Segal BM , ConstantinescuCS, RaychaudhuriA et al.: Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing–remitting multiple sclerosis: a Phase II, double-blind, placebo-controlled, randomised, dose-ranging study.Lancet Neurol.7(9) , 796–804 (2008).
  • Hofstetter HH , IbrahimSM, KoczanD et al.: Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis.Cell Immunol.237(2) , 123–130 (2005).
  • Suntharalingam G , PerryMR, WardS et al.: Cytokine storm in a Phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.N. Engl. J. Med.355(10) , 1018–1028 (2006).
  • Jiang H , MiloR, SwovelandP et al.: Interferon β-1b reduces interferon γ-induced antigen-presenting capacity of human glial and B cells.J. Neuroimmunol.61(1) , 17–25 (1995).
  • Panitch HS , HirschRL, SchindlerJ, JohnsonKP: Treatment of multiple sclerosis with g-interferon: exacerbations associated with activation of the immune system.Neurology37(7) , 1097–1102 (1987).
  • Teleshova N , BaoW, KivisakkP et al.: Elevated CD40 ligand expressing blood T-cell levels in multiple sclerosis are reversed by interferon-β treatment.Scand. J. Immunol.51(3) , 312–320 (2000).
  • Genc K , DonaDL, RederAT: Increased CD80+ B cells in active multiple sclerosis and reversal by interferon β-1b therapy.J. Clin. Invest.99(11) , 2664–2671 (1997).
  • Dhib-Jalbut S : Mechanisms of interferon-β action in multiple sclerosis.Mult. Scler.3(6) , 397–401 (1997).
  • Rep MH , SchrijverHM, van Lopik T et al.: Interferon (IFN)-β treatment enhances CD95 and interleukin 10 expression but reduces interferon-γ producing T cells in MS patients. J. Neuroimmunol.96(1) , 92–100 (1999).
  • Calabresi PA , TranquillLR, DambrosiaJM et al.: Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon β-1b.Ann. Neurol.41(5) , 669–674 (1997).
  • Dhib-Jalbut S , JiangH, WilliamsGJ: The effect of interferon β-1b on lymphocyte-endothelial cell adhesion.J. Neuroimmunol.71(1–2) , 215–222 (1996).
  • Schreiner B , MitsdoerfferM, KieseierBC et al.: Interferon-β enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.J. Neuroimmunol.155(1–2) , 172–182 (2004).
  • Shapiro S , GalboizY, LahatN, KinartyA, MillerA: The ‘immunological-synapse‘ at its APC side in relapsing and secondary-progressive multiple sclerosis: modulation by interferon-β.J. Neuroimmunol.144(1–2) , 116–124 (2003).
  • Gran B , TranquillLR, ChenM et al.: Mechanisms of immunomodulation by glatiramer acetate.Neurology55(11) , 1704–1714 (2000).
  • Neuhaus O , FarinaC, WekerleH, HohlfeldR: Mechanisms of action of glatiramer acetate in multiple sclerosis.Neurology56(6) , 702–708 (2001).
  • Duda PW , SchmiedMC, CookSL, KriegerJI, HaflerDA: Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.J. Clin. Invest.105(7) , 967–976 (2000).
  • Weber MS , StarckM, WagenpfeilS et al.: Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo.Brain127(Pt 6) , 1370–1378 (2004).
  • Weber MS , Prod‘hommeT, YoussefS et al.: Type II monocytes modulate T cell-mediated central nervous system autoimmune disease.Nat. Med.13(8) , 935–943 (2007).
  • Maier K , KuhnertAV, TaheriN et al.: Effects of glatiramer acetate and interferon-β on neurodegeneration in a model of multiple sclerosis:a comparative study.Am. J. Pathol.169(4) , 1353–1364 (2006).
  • Yednock TA , CannonC, FritzLC et al.: Prevention of experimental autoimmune encephalomyelitis by antibodies against a4b1 integrin.Nature356(6364) , 63–66 (1992).
  • Stuve O , MarraCM, JeromeKR et al.: Immune surveillance in multiple sclerosis patients treated with natalizumab.Ann. Neurol.59(5) , 743–747 (2006).
  • Stuve O : The effects of natalizumab on the innate and adaptive immune system in the central nervous system.J. Neurol. Sci.274(1–2) , 39–41 (2008).
  • Massacesi L , ParigiA, BarilaroA et al.: Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging.Arch. Neurol.62(12) , 1843–1847 (2005).
  • Amato MP , PracucciG, PonzianiG et al.: Long-term safety of azathioprine therapy in multiple sclerosis.Neurology43(4) , 831–833 (1993).
  • Casetta I , IulianoG, FilippiniG: Azathioprine for multiple sclerosis.Cochrane Database Syst. Rev. (4) , CD003982 (2007).
  • Fox EJ : Mechanism of action of mitoxantrone.Neurology63(12 Suppl. 6) , S15–S18 (2004).
  • Martinelli Boneschi F , RovarisM, CapraR, ComiG: Mitoxantrone for multiple sclerosis.Cochrane Database Syst. Rev. (4) , CD002127 (2005).
  • Fox EJ : Management of worsening multiple sclerosis with mitoxantrone: a review.Clin. Ther.28(4) , 461–474 (2006).
  • Sipe JC , RomineJS, KoziolJA et al.: Cladribine in treatment of chronic progressive multiple sclerosis.Lancet344(8914) , 9–13 (1994).
  • Sipe JC , RomineJS, KoziolJA et al.: Development of cladribine treatment in multiple sclerosis.Mult. Scler.1(6) , 343–347 (1996).
  • Rice GP , FilippiM, ComiG: Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group.Neurology54(5) , 1145–1155 (2000).
  • Brousil JA , RobertsRJ, SchleinAL: Cladribine: an investigational immunomodulatory agent for multiple sclerosis.Ann. Pharmacother.40(10) , 1814–1821 (2006).
  • Stelmasiak Z , SolskiJ, NowickiJ et al.: Effect of parenteral cladribine on relapse rates in patients with relapsing forms of multiple sclerosis: results of a 2-year, double-blind, placebo-controlled, crossover study.Mult. Scler.15(6) , 767–770 (2009).
  • Budde K , SchmouderRL, BrunkhorstR et al.: First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients.J. Am. Soc. Nephrol.13(4) , 1073–1083 (2002).
  • Fujino M , FuneshimaN, KitazawaY et al.: Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment.J. Pharmacol. Exp. Ther.305(1) , 70–77 (2003).
  • Mehling M , BrinkmannV, AntelJ et al.: FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.Neurology71(16) , 1261–1267 (2008).
  • Brinkmann V , CysterJG, HlaT: FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function.Am. J. Transplant.4(7) , 1019–1025 (2004).
  • Mandala S , HajduR, BergstromJ et al.: Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists.Science296(5566) , 346–349 (2002).
  • Matloubian M , LoCG, CinamonG et al.: Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1.Nature427(6972) , 355–360 (2004).
  • O‘Connor P , ComiG, MontalbanX et al.: Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a Phase II extension study.Neurology72(1) , 73–79 (2009).
  • Waldmann TA : Anti-Tac (daclizumab, Zenapax®) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.J. Clin. Immunol.27(1) , 1–18 (2007).
  • Bielekova B , RichertN, HowardT et al.: Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β.Proc. Natl Acad. Sci. USA101(23) , 8705–8708 (2004).
  • Rose JW , WattHE, WhiteAT, CarlsonNG: Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody.Ann. Neurol.56(6) , 864–867 (2004).
  • Bielekova B , CatalfamoM, Reichert-ScrivnerS et al.: Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis.Proc. Natl Acad. Sci. USA103(15) , 5941–5946 (2006).
  • Coles AJ , CompstonDA, SelmajKW et al.: Alemtuzumab vs. interferon β-1a in early multiple sclerosis.N. Engl. J. Med.359(17) , 1786–1801 (2008).
  • Cox AL , ThompsonSA, JonesJL et al.: Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.Eur. J. Immunol.35(11) , 3332–3342 (2005).
  • Coles AJ , WingM, SmithS et al.: Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis.Lancet354(9191) , 1691–1695 (1999).
  • Jones JL , PhuahCL, CoxAL et al.: IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).J. Clin. Invest. (2009).
  • Herrmann ML , SchleyerbachR, KirschbaumBJ: Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases.Immunopharmacology47(2–3) , 273–289 (2000).
  • Korn T , MagnusT, ToykaK, JungS: Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide – mechanisms independent of pyrimidine depletion.J. Leukoc. Biol.76(5) , 950–960 (2004).
  • Massacesi L , AbbamondiAL, SarloF, AmaducciL: The control of experimental allergic encephalomyelitis with retinoic acid. Further studies.Riv. Neurol.57(3) , 166–169 (1987).
  • Roberts AB , SpornMB: Mechanistic interrelationships between two superfamilies: the steroid/retinoid receptors and transforming growth factor-β.Cancer Surv.14 , 205–220 (1992).
  • Mucida D , ParkY, KimG et al.: Reciprocal Th17 and regulatory T cell differentiation mediated by retinoic acid.Science317(5835) , 256–260 (2007).
  • Bettelli E , OukkaM, KuchrooVK: Th-17 cells in the circle of immunity and autoimmunity.Nat. Immunol.8(4) , 345–350 (2007).
  • Korn T , ReddyJ, GaoW et al.: Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation.Nat. Med.13(4) , 423–431 (2007).
  • Kohm AP , CarpentierPA, AngerHA, MillerSD: Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis.J. Immunol.169(9) , 4712–4716 (2002).
  • Viglietta V , Baecher-AllanC, WeinerHL, HaflerDA: Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis.J. Exp. Med.199(7) , 971–979 (2004).
  • Beriou G , CostantinoCM, AshleyCW et al.: IL-17 producing human peripheral regulatory T cells retain suppressive function.Blood113(18) , 4240–4249 (2009).
  • Zhou L , Ivanov,II, SpolskiR et al.: IL-6 programs Th-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways.Nat. Immunol.8(9) , 967–974 (2007).
  • Wei L , LaurenceA, EliasKM, O‘SheaJJ: IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner.J. Biol. Chem.282(48) , 34605–34610 (2007).
  • Huber M , BrustleA, ReinhardK et al.: IRF4 is essential for IL-21-mediated induction, amplification, and stabilization of the Th17 phenotype.Proc. Natl Acad. Sci. USA105(52) , 20846–20851 (2008).
  • Wolk K , SabatR: Interleukin-22: a novel T- and NK-cell derived cytokine that regulates the biology of tissue cells.Cytokine Growth Factor Rev.17(5) , 367–380 (2006).
  • Chung Y , YangX, ChangSH et al.: Expression and regulation of IL-22 in the IL-17-producing CD4+ T lymphocytes.Cell Res.16(11) , 902–907 (2006).
  • Zheng Y , ValdezPA, DanilenkoDM et al.: Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens.Nat. Med.14(3) , 282–289 (2008).
  • Kreymborg K , EtzenspergerR, DumoutierL et al.: IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis.J. Immunol.179(12) , 8098–8104 (2007).
  • Fitzgerald DC , CiricB, TouilT et al.: Suppressive effect of IL-27 on encephalitogenic Th17 cells and the effector phase of experimental autoimmune encephalomyelitis.J. Immunol.179(5) , 3268–3275 (2007).
  • Awasthi A , CarrierY, PeronJP et al.: A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells.Nat. Immunol.8(12) , 1380–1389 (2007).
  • Fitzgerald DC , ZhangGX, El-BehiM et al.: Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells.Nat. Immunol.8(12) , 1372–1379 (2007).
  • Dardalhon V , AwasthiA, KwonH et al.: IL-4 inhibits TGF-β-induced Foxp3+ T cells and, together with TGF-β, generates IL-9+ IL-10+ Foxp3- effector T cells.Nat. Immunol.9(12) , 1347–1355 (2008).
  • Veldhoen M , UyttenhoveC, van Snick J et al.: Transforming growth factor-β ‘reprograms‘ the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat. Immunol.9(12) , 1341–1346 (2008).
  • Weinshenker BG , BassB, KarlikS, EbersGC, RiceGP: An open trial of OKT3 in patients with multiple sclerosis.Neurology41(7) , 1047–1052 (1991).
  • Lindsey JW , HodgkinsonS, MehtaR et al.: Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis.Ann. Neurol.36(2) , 183–189 (1994).
  • Lindsey JW , HodgkinsonS, MehtaR et al.: Phase 1 clinical trial of chimeric monoclonal anti-CD4 antibody in multiple sclerosis.Neurology44(3 Pt 1) , 413–419 (1994).
  • van Oosten BW , LaiM, BarkhofF et al.: A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis.Mult. Scler.1(6) , 339–342 (1996).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.